Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7623

Shown on this page

Current sort

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions: TRS01, FDA approved steroid eye drop (masked); Drug
Lead sponsor: Tarsier Pharma; Industry
Eligibility: 0 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 180
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more

Conditions: Spinal Duraplasty
Interventions: Adherus Dural Sealant System, DuraSeal Exact Dural Sealant System; Device
Lead sponsor: Stryker Craniomaxillofacial; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 14
States / cities: Duarte, California • Sacramento, California • Stanford, California + 9 more

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 752
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more

Conditions: Acute Kidney Injury
Interventions: Selective Cytopheretic Device, Standard of Care; Device · Other
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more

Conditions: Diabetic Retinopathy (DR)
Interventions: automatic analysis of fundus images performed by the software tool based on artificial intelligence; Device
Lead sponsor: Centervue SpA; Industry
Eligibility: 22 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 1,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 928
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more

Conditions: Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
Interventions: Bevacizumab, Carboplatin, Cisplatin, Docetaxel, Fluorouracil, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 777
States / cities: Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 472 more

Conditions: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions: ianalumab, thrombopoietin receptor agonist (TPO-RA); Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Torrance, California + 16 more

Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Transthyretin Amyloid Cardiomyopathy
Interventions: ALXN2220, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 36
States / cities: Irvine, California • La Jolla, California • Palo Alto, California + 30 more

Clinical trials in Jacksonville, Florida

Filter and sort this location

Institutions in Jacksonville

Live official records

TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Adherus™ Dural Sealant in Spinal Procedures

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

Preliminary Assessment of an Automated Tool for Diabetic Retinopathy Screening

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM